Literature DB >> 21402843

Antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae isolates from elderly patients with pneumonia and acute exacerbation of chronic obstructive pulmonary disease.

Emilio Pérez-Trallero1, José M Marimón, Julián Larruskain, Marta Alonso, María Ercibengoa.   

Abstract

In the elderly, Streptococcus pneumoniae is the most common cause of pneumonia and one of the most frequently isolated pathogens in cases of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). This study was conducted to compare the pneumococcal isolates obtained during episodes of AECOPD and pneumonia in patients of ≥65 years old and to analyze whether in patients with AECOPD and pneumonia within a short interval, the same isolate caused both episodes. This laboratory-based study was performed between 2005 and 2008. Pneumococcal isolates from episodes of pneumonia (n = 401) and AECOPD (n = 398), matched one-to-one by date of isolation, were characterized. The serotypes and genotypes of other pneumococcal isolates causing pneumonia and AECOPD in the same patient were compared. In patients with pneumonia, COPD as an underlying disease was not associated with more-drug-resistant pneumococci. In contrast, isolates causing AECOPD showed higher rates of resistance than those causing pneumonia. Serotypes 1, 3, and 7F were more frequent in pneumonia. The same pneumococcus was involved in 25.7% (9/35 patients) of patients with two consecutive AECOPD episodes but in only 6.3% (2/32 patients) of COPD patients with pneumonia and exacerbation (Fisher's exact test; P = 0.047). Less invasive serotypes were isolated more often in AECOPD and were more resistant to antimicrobials. The presence of a specific pneumococcal serotype in AECOPD does not predict the etiology of subsequent pneumonia.

Entities:  

Mesh:

Year:  2011        PMID: 21402843      PMCID: PMC3101435          DOI: 10.1128/AAC.01546-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children.

Authors:  Angela B Brueggemann; Timothy E A Peto; Derrick W Crook; Jay C Butler; Karl G Kristinsson; Brian G Spratt
Journal:  J Infect Dis       Date:  2004-08-25       Impact factor: 5.226

2.  Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.

Authors:  Javier Aspa; Olga Rajas; Felipe Rodríguez de Castro; José Blanquer; Rafael Zalacain; Asunción Fenoll; Rosa de Celis; Antonio Vargas; Francisco Rodríguez Salvanés; Pedro Pablo España; Jordi Rello; Antoni Torres
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

3.  Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae.

Authors:  A Sandgren; K Sjostrom; B Olsson-Liljequist; B Christensson; A Samuelsson; G Kronvall; B Henriques Normark
Journal:  J Infect Dis       Date:  2004-02-16       Impact factor: 5.226

4.  Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance.

Authors:  Jörg J Ruhe; Rodrigo Hasbun
Journal:  Clin Infect Dis       Date:  2003-04-22       Impact factor: 9.079

5.  Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006.

Authors:  Heather J Adam; Daryl J Hoban; Alfred S Gin; George G Zhanel
Journal:  Int J Antimicrob Agents       Date:  2009-04-01       Impact factor: 5.283

6.  Molecular characterization of erythromycin-resistant clinical isolates of the four major antimicrobial-resistant Spanish clones of Streptococcus pneumoniae (Spain23F-1, Spain6B-2, Spain9V-3, and Spain14-5).

Authors:  José M Marimón; Luis Iglesias; Diego Vicente; Emilio Pérez-Trallero
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

7.  Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected.

Authors:  E Calbo; E Valdés; A Ochoa de Echagüen; A Fleites; L Molinos; M Xercavins; N Freixas; M Rodríguez-Carballeira; J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-10       Impact factor: 3.267

8.  Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine.

Authors:  E Pérez-Trallero; J M Marimon; M Ercibengoa; D Vicente; E G Pérez-Yarza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-20       Impact factor: 3.267

9.  Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes.

Authors:  Werner C Albrich; Dominique L Monnet; Stephan Harbarth
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

10.  Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia.

Authors:  Angel Vila-Corcoles; Ferran Bejarano-Romero; Elisabeth Salsench; Olga Ochoa-Gondar; Cinta de Diego; Frederic Gomez-Bertomeu; Xavier Raga-Luria; Xavier Cliville-Guasch; Victoria Arija
Journal:  BMC Infect Dis       Date:  2009-03-25       Impact factor: 3.090

View more
  12 in total

1.  Streptococcus pneumoniae Colonization Disrupts the Microbial Community within the Upper Respiratory Tract of Aging Mice.

Authors:  Netusha Thevaranjan; Fiona J Whelan; Alicja Puchta; Eta Ashu; Laura Rossi; Michael G Surette; Dawn M E Bowdish
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

2.  Community-acquired pneumonia in patients with chronic obstructive pulmonary disease.

Authors:  Aykut Cilli
Journal:  Curr Infect Dis Rep       Date:  2015-01       Impact factor: 3.725

3.  Impaired NLRP3 inflammasome function in elderly mice during influenza infection is rescued by treatment with nigericin.

Authors:  Heather W Stout-Delgado; Sarah E Vaughan; Anushree C Shirali; Richard J Jaramillo; Kevin S Harrod
Journal:  J Immunol       Date:  2012-02-10       Impact factor: 5.422

4.  Chemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract.

Authors:  Bruno Corsini; Roberto Díez-Martínez; Leire Aguinagalde; Fernando González-Camacho; Esther García-Fernández; Patricia Letrado; Pedro García; Jose Yuste
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

5.  Antibiotic expected effectiveness and cost under real life microbiology: evaluation of ertapenem and ceftriaxone in the treatment of community-acquired pneumonia for elderly patients in Spain.

Authors:  Santiago Grau; Virginia Lozano; Amparo Valladares; Rafael Cavanillas; Yang Xie; Gonzalo Nocea
Journal:  Clinicoecon Outcomes Res       Date:  2014-02-13

6.  Dynamics of Streptococcus pneumoniae serotypes causing acute otitis media isolated from children with spontaneous middle-ear drainage over a 12-year period (1999-2010) in a region of northern Spain.

Authors:  Marta Alonso; José M Marimon; María Ercibengoa; Eduardo G Pérez-Yarza; Emilio Pérez-Trallero
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

Review 7.  Fine particulate matter in acute exacerbation of COPD.

Authors:  Lei Ni; Chia-Chen Chuang; Li Zuo
Journal:  Front Physiol       Date:  2015-10-23       Impact factor: 4.566

Review 8.  Current Status of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  De-Shun Liu; Xiu-Di Han; Xue-Dong Liu
Journal:  Chin Med J (Engl)       Date:  2018-05-05       Impact factor: 2.628

9.  Independent factors associated with pneumonia among hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Songsong Yu; Qiuhong Fang; Yinjuan Li
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

10.  Bacterial composition of nasal discharge in children based on highly accurate 16S rRNA gene sequencing analysis.

Authors:  Kaoru Haro; Midori Ogawa; Mitsumasa Saito; Koichi Kusuhara; Kazumasa Fukuda
Journal:  Sci Rep       Date:  2020-11-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.